HyperaFRA:HM6A -1.12%92 FCF Margin % is 18.96% as of Mar. 2026, which is 7% below its 10-year median of 20.30. GuruFocus rates FRA:HM6A with a GF Score™ of 92/100 and a GF Value™ of €5.23 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Hypera ranks better than 89.74% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Hypera's Free Cash Flow for the
three
months ended in Mar. 2026 was €63 Mil. Hypera's Revenue for the
three
months ended in Mar. 2026 was €334 Mil. Therefore, Hypera's FCF Margin % for the quarter that ended in Mar. 2026 was 18.96%.
The historical rank and industry rank for Hypera's FCF Margin % or its related term are showing as below:
FRA:HM6A'
s FCF Margin % Range Over the Past 10 Years
Min: -18.2 Med: 20.3 Max: 23.75
Current: 20.95
During the past 13 years, the highest FCF Margin % of Hypera was 23.75%. The lowest was -18.20%. And the median was 20.30%.
FRA:HM6A's FCF Margin % is ranked better than 89.74% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs FRA:HM6A: 20.95
Hypera FCF Margin % Related Terms
Hypera FCF Margin % Historical Data
* Premium members only.
The historical data trend for Hypera's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HM6A vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hypera's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hypera FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hypera's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Hypera's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hypera (FRA:HM6A) has a FCF Margin % of 18.96% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Hypera and its competitors. This is near median its historical median of 20.30. According to the industry distribution chart, Hypera ranks #98 out of 955 companies in the Drug Manufacturers industry, placing it in the top 10.3%.
Is Hypera's FCF Margin % too high?
Hypera's current FCF Margin % of 18.96% is near median its 10-year median of 20.30. The Drug Manufacturers industry median FCF Margin % is 2.51. Hypera's value of 18.96% is 655.4% above this industry median. Based on the distribution chart, Hypera ranks #98 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hypera has a GF Score™ of 92/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hypera's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hypera ranks #98 out of 955 companies for FCF Margin %. This places Hypera in the top 10% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.51. Hypera's value of 18.96% is 655.4% above this benchmark. While the company's 10-year median is 20.30 vs. the industry median of 2.51, Hypera has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hypera's current FCF Margin % of 18.96% is 655.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Hypera and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hypera's current FCF Margin % is 18.96%, which is near median its own 10-year median of 20.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hypera stock overvalued right now?
Based on GuruFocus' analysis, Hypera (FRA:HM6A) is currently considered Possible Value Trap. The stock's GF Value™ is €5.23, compared to a current price of €3.54 — trading 32.3% below its estimated fair value. The current FCF Margin % is 18.96%, which is near median its 10-year median of 20.30 and 655.4% above the Drug Manufacturers industry median of 2.51. Hypera's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Hypera (FRA:HM6A), the current FCF Margin % is 18.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hypera (FRA:HM6A) Overvalued in 2026?
Based on GuruFocus' analysis, Hypera stock appears to be undervalued.
The current stock price of €3.54 is trading 32.3% below its estimated GF Value™ of €5.23.
GuruFocus considers Hypera to be Possible Value Trap.
Key valuation signals for FRA:HM6A:
FCF Margin %: 18.96% (near median its 10-year median of 20.30)
GF Value™: €5.23 vs. price of €3.54 (32.3% below fair value)
Industry Position: 655.4% above the Drug Manufacturers median (#98 of 955)
No single metric tells the full story. See the FRA:HM6A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hypera SA is a specialty and generic drug manufacturing company. The company operates in the prescription medicines, over-the-counter (OTC) medicines, branded generics, and generics, and skincare segments within the retail pharmaceutical market. The company also has a wide sales and distribution structure. The company's product portfolio includes key brands in Gastroenterology, Pain, Sun Protection, Skin Moisture, and Cleansing within the over-the-counter (OTC) and Skincare segments, as well as new products in Cardiology, Central Nervous System, and Respiratory System within the prescription medicines segment.
92GF Score
Get the complete analysis for FRA:HM6A
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HM6A has been successfully added to your 
